Scientific Library
- Acute Coronary Syndrom
- ASCVD Prevention
- Bifurcation Stenting
- Cardio-Oncology
- Congestive Heart Failure
- DAPT Duration
- Drug Coated Balloon
- Fractional Flow Reserve
- IVUS Guidance
- Optical Coherence Tomography
- Pulmonary Hypertension
- Rotational Atherectomy
- Shear Stress
- Stenting Left Main
- Transcatheter Aortic Valve Replacement
- Percutaneous LAA Occlusion
- Mitral/Tricuspid Valvular Disease
- Other Relevant Articles
-
Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: Insights from the randomized GLOBAL LEADERS trialPW Serruys; M Tomaniak; P Chichareon et al. -
Antibody-Based Ticagrelor Reversal Agent in Healthy VolunteersDL Bhatt, CV Pollack, JS Lee et al.
-
Dual Antiplatelet Therapy Duration: Reconciling the InconsistenciesCosta F, Windecker S, Valgimigli M.
-
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial FibrillationCannon CP, Bhatt DL, Oldgren J et al.
-
Dual Antiplatelet TherapyIs It Time to Cut the Cord With Aspirin?KM Ziada; DJ Moliterno et al.
-
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCIGibson CM, Mehran R, Bode C et al.
-
ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy JACC Guideline Comparison: JACC State-of-the-Art ReviewD Capodanno, F Alfonso, GN Levine et al.
-
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicenter, open-label, randomized superiority trialP Vranckx, M Valgimigli, P Jüni et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
